Insulet Co. (NASDAQ:PODD) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. trimmed its stake in shares of Insulet Co. (NASDAQ:PODD) by 1.3% in the third quarter, Holdings Channel.com reports. The fund owned 84,300 shares of the medical instruments supplier’s stock after selling 1,102 shares during the period. Rockefeller Capital Management L.P.’s holdings in Insulet were worth $19,609,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tidal Investments LLC raised its position in shares of Insulet by 58.8% during the 1st quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock worth $697,000 after purchasing an additional 1,504 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Insulet by 7.1% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 11,607 shares of the medical instruments supplier’s stock worth $1,996,000 after purchasing an additional 770 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Insulet by 271.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,336 shares of the medical instruments supplier’s stock worth $270,000 after purchasing an additional 976 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its position in shares of Insulet by 159.2% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 156 shares during the last quarter. Finally, Mather Group LLC. raised its position in shares of Insulet by 50.3% during the 2nd quarter. Mather Group LLC. now owns 469 shares of the medical instruments supplier’s stock worth $95,000 after purchasing an additional 157 shares during the last quarter.

Insulet Stock Down 0.1 %

Shares of Insulet stock opened at $266.78 on Monday. The company has a fifty day moving average price of $244.40 and a 200 day moving average price of $214.14. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The stock has a market cap of $18.71 billion, a price-to-earnings ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22.

Analyst Upgrades and Downgrades

PODD has been the subject of several recent analyst reports. Canaccord Genuity Group lifted their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Raymond James lifted their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Piper Sandler lifted their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Morgan Stanley lifted their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, Barclays lifted their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.